276 related articles for article (PubMed ID: 32772754)
1. Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer.
Petrykey K; Andelfinger GU; Laverdière C; Sinnett D; Krajinovic M
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):865-883. PubMed ID: 32772754
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
3. Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Corremans R; Adão R; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):204-215. PubMed ID: 30244497
[TBL] [Abstract][Full Text] [Related]
4. Current views on anthracycline cardiotoxicity.
Mele D; Nardozza M; Spallarossa P; Frassoldati A; Tocchetti CG; Cadeddu C; Madonna R; Malagù M; Ferrari R; Mercuro G
Heart Fail Rev; 2016 Sep; 21(5):621-34. PubMed ID: 27230651
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular disease in survivors of childhood cancer.
Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
[TBL] [Abstract][Full Text] [Related]
6. An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies.
Zerra P; Cochran TR; Franco VI; Lipshultz SE
Expert Opin Pharmacother; 2013 Aug; 14(11):1497-513. PubMed ID: 23705955
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline-based chemotherapy.
Loucks CM; Yan K; Tanoshima R; Ross CJD; Rassekh SR; Carleton BC
Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():95-99. PubMed ID: 33900042
[TBL] [Abstract][Full Text] [Related]
8. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Cheuk DK; Sieswerda E; van Dalen EC; Postma A; Kremer LC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008011. PubMed ID: 27552363
[TBL] [Abstract][Full Text] [Related]
9. Predicting and Preventing Anthracycline-Related Cardiotoxicity.
Armenian S; Bhatia S
Am Soc Clin Oncol Educ Book; 2018 May; 38():3-12. PubMed ID: 30231396
[TBL] [Abstract][Full Text] [Related]
10. Hypertension Susceptibility Loci are Associated with Anthracycline-related Cardiotoxicity in Long-term Childhood Cancer Survivors.
Hildebrandt MAT; Reyes M; Wu X; Pu X; Thompson KA; Ma J; Landstrom AP; Morrison AC; Ater JL
Sci Rep; 2017 Aug; 7(1):9698. PubMed ID: 28851949
[TBL] [Abstract][Full Text] [Related]
11. Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.
Lipshultz SE; Diamond MB; Franco VI; Aggarwal S; Leger K; Santos MV; Sallan SE; Chow EJ
Paediatr Drugs; 2014 Oct; 16(5):373-89. PubMed ID: 25134924
[TBL] [Abstract][Full Text] [Related]
12. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
14. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study.
Abdel-Qadir H; Bobrowski D; Zhou L; Austin PC; Calvillo-Argüelles O; Amir E; Lee DS; Thavendiranathan P
J Am Heart Assoc; 2021 Jan; 10(2):e018393. PubMed ID: 33401953
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline cardiotoxicity.
Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
[TBL] [Abstract][Full Text] [Related]
16. Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity.
Khan AA; Ashraf A; Singh R; Rahim A; Rostom W; Hussain M; Renner I; Collins NJ
Intern Med J; 2017 Jan; 47(1):104-109. PubMed ID: 27800661
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.
Bhagat A; Kleinerman ES
Adv Exp Med Biol; 2020; 1257():181-192. PubMed ID: 32483740
[TBL] [Abstract][Full Text] [Related]
18. Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors.
Sadurska E
Pediatr Cardiol; 2015 Aug; 36(6):1112-9. PubMed ID: 25939787
[TBL] [Abstract][Full Text] [Related]
19. Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients.
Ruiz-Pinto S; Pita G; Martín M; Alonso-Gordoa T; Barnes DR; Alonso MR; Herraez B; García-Miguel P; Alonso J; Pérez-Martínez A; Cartón AJ; Gutiérrez-Larraya F; García-Sáenz JA; Benítez J; Easton DF; Patiño-García A; González-Neira A
Breast Cancer Res Treat; 2018 Jan; 167(1):249-256. PubMed ID: 28913729
[TBL] [Abstract][Full Text] [Related]
20. Is there scope for better individualisation of anthracycline cancer chemotherapy?
Sallustio BC; Boddy AV
Br J Clin Pharmacol; 2021 Feb; 87(2):295-305. PubMed ID: 33118175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]